

NOV. 4. 2004 3:12PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 9452 P. 1

NOV 04 2004

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0051
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCEUnder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/616,959
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSA et al.
Art Unit	1626
Examiner Name	Davis, Zinna Northington
Total Number of Pages in This Submission	DEAV2002/0048 US NP

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <input type="checkbox"/> Response to Restriction
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Remarks
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Information Disclosure Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Barbara E. Kurys		
Date	November 04, 2004	Reg. No.	34,650

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: 3)

Signature			
Typed or printed name	Generia Walker	Date	November 04, 2004

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV. 4. 2004 3:12PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 9452 P. 2

NOV 04 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Elisabeth DeFossa et al

Application No.: 10/616,959

Examiner: Davis, Zinna Northington

Art Unit: 1625

Filed: July 11, 2003

Title: UREA-AND URETHANE-
SUBSTITUTED ACYLUREAS,
PROCESS FOR THEIR
PREPARATION AND THEIR USE

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on

11-4-2004

Date of Transmission

Barbara Walker
Signature

Response To Restriction Requirement

Mail Stop Art Unit 1625
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

This paper is filed in response to the Office Action of June 4, 2004.

In response to the Restriction Requirement imposed by the Examiner in the above-referenced Office Action, Applicant hereby provisionally elects Group I. Applicant hereby provisionally elects the species that is Example 13 in Table 1 on page 29 of the specification.

The Examiner has requested that Applicant list all claims readable on the species election. Claims that read on the species include claims 1-7.

The Commissioner is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication to our Deposit Account No. 18-1982. If a fee is required for an extension of time under 37 C.F.R. Section 1.136 not accounted for above, such extension is requested and should also be charged to our Deposit Account.

Respectfully submitted,

Barbara E. Kurys
Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0048 US NP